CDK2-activated TRIM32 phosphorylation and nuclear translocation promotes radioresistance in triple-negative breast cancer

• Published in: Journal of advanced research Vol. 61; pp. 239 - 251
• Main Authors: Tang, Jianming, Li, Jing, Lian, Jiayan, Huang, Yumei, Zhang, Yaqing, Lu, Yanwei, Zhong, Guansheng, Wang, Yaqi, Zhang, Zhitao, Bai, Xin, Fang, Min, Wu, Luming, Shen, Haofei, Wu, Jingyuan, Wang, Yiqing, Zhang, Lei, Zhang, Haibo
• Format: Journal Article
• Language: English
• Published: Egypt Elsevier B.V 01.07.2024; Elsevier
• Subjects: Animals; CDK2; Cell Line, Tumor; Cell Nucleus - metabolism; Cell Proliferation; Cyclin-Dependent Kinase 2 - metabolism; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Nuclear translocation; Phosphorylation; Radiation Tolerance; Radioresistance; STAT3 Transcription Factor - metabolism; Transcription Factors - metabolism; TRIM32; Tripartite Motif Proteins - genetics; Tripartite Motif Proteins - metabolism; Triple Negative Breast Neoplasms - metabolism; Triple Negative Breast Neoplasms - radiotherapy; Triple-negative breast cancer; Ubiquitin-Protein Ligases - genetics; Ubiquitin-Protein Ligases - metabolism; Radioresistance; Nuclear translocation; TRIM32; CDK2; Triple-negative breast cancer
• ISSN: 2090-1232; 2090-1224; 2090-1224
• DOI: 10.1016/j.jare.2023.09.011

[Display omitted] •Radiotherapy promotes the binding of CDK2 and TRIM32, thus leading to increased CDK2-dependent phosphorylation of TRIM32 at serines 328 and 339.•Cis-trans isomerization of TRIM32 recruit PIN1, which resulting in importin α3 binding to TRIM32 and contributing to its nuclear translocation.•Nuclear TRIM32 inhibits TC45-dephosphorylated STAT3, Leading to increased transcription of STAT3 and radioresistance in triple-negative breast cancer (TNBC).•Regulating the CDK2/TRIM32/STAT3 pathway is a promising strategy for reducing radioresistance in TNBC, which is important for TNBC therapy. Despite radiotherapy being one of the major treatments for triple-negative breast cancer (TNBC), new molecular targets for its treatment are still required due to radioresistance. CDK2 plays a critical role in TNBC. However, the mechanism by which CDK2 promotes TNBC radioresistance remains to be clearly elucidated. We aimed to elucidate the relationship between CDK2 and TRIM32 and the regulation mechanism in TNBC. We performed immunohistochemical staining to detect nuclear TRIM32, CDK2 and STAT3 on TNBC tissues. Western blot assays and PCR were used to detect the protein and mRNA level changes. CRISPR/Cas9 used to knock out CDK2. shRNA-knockdown and transfection assays also used to knock out target genes. GST pull-down analysis, immunoprecipitation (IP) assay and in vitro isomerization analysis also used. Tumorigenesis studies also used to verify the results in vitro. Herein, tripartite motif-containing protein 32 (TRIM32) is revealed as a substrate of CDK2. Radiotherapy promotes the binding of CDK2 and TRIM32, thus leading to increased CDK2-dependent phosphorylation of TRIM32 at serines 328 and 339. This causes the recruitment of PIN1, involved in cis–trans isomerization of TRIM32, resulting in importin α3 binding to TRIM32 and contributing to its nuclear translocation. Nuclear TRIM32 inhibits TC45-dephosphorylated STAT3, Leading to increased transcription of STAT3 and radioresistance in TNBC. These results were validated by clinical prognosis confirmed by the correlative expressions of the critical components of the CDK2/TRIM32/STAT3 signaling pathway. Our findings demonstrate that regulating the CDK2/TRIM32/STAT3 pathway is a promising strategy for reducing radioresistance in TNBC.